Enhancing Oxygen,
Fueling Life
Targeting Treatments for Hypoxia

Improving Oxygen Availability

Novel Mechanism of Action

Lead drug trans sodium crocetinate (TSC) enhances the oxygen diffusion process, supporting normal, physiologic levels of oxygen diffusion at uptake and delivery.

Selective for Hypoxic Tissue

In animal models, TSC’s mechanism of action enhanced oxygen availability to hypoxic tissue without oversupplying normoxic tissue.

Demonstrated Safety Profile

TSC has been safe and well tolerated in over 200 subjects dosed in prior preclinical and clinical studies.


Potential Treatment for
Hypoxia-related Indications

Diffusion Pharmaceuticals is actively evaluating the clinical effects of TSC on oxygenation and hypoxia-related indications, building upon data from prior clinical studies in peripheral artery disease, glioblastoma multiform (GBM) brain cancer, stroke, and COVID-19.


The latest news, press releases, and more.

Back to top